← FDA DRUG APPROVALS

FDA ANDA · ANDA074093

DILTIAZEM HYDROCHLORIDE

Sponsor: CHARTWELL MOLECULES

APPLICATION
ANDA074093
TYPE
ANDA
ORIGINAL APPROVAL
1992-11-05
LATEST ACTION
1999-10-04
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 120MG · TABLET · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 60MG · TABLET · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 90MG · TABLET · ORAL
DILTIAZEM HYDROCHLORIDEDiscontinued
DILTIAZEM HYDROCHLORIDE 30MG · TABLET · ORAL

Approval history

1999-10-04Manufacturing (CMC) · Supplement 14AP
1998-01-29Manufacturing (CMC) · Supplement 13AP
1997-01-28Labeling · Supplement 12AP
1997-01-16Labeling · Supplement 11AP
1996-12-11Manufacturing (CMC) · Supplement 10AP
1996-04-29Manufacturing (CMC) · Supplement 9AP
1995-11-15Labeling · Supplement 8AP
1995-11-07Manufacturing (CMC) · Supplement 6AP
1995-11-07Manufacturing (CMC) · Supplement 7AP
1995-02-08Manufacturing (CMC) · Supplement 5AP
1994-11-23Manufacturing (CMC) · Supplement 4AP
1994-11-23Manufacturing (CMC) · Supplement 3AP
1994-05-10Labeling · Supplement 1AP
1994-04-28Manufacturing (CMC) · Supplement 2AP
1992-11-05OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →